HELP · Cybin

The thesis

Helus Pharma is more likely to lag the S&P 500 over the next three months. The company has one late-stage program, the APPROACH Phase 3 trial of HLP003 in major depressive disorder, and the shares have fallen into the wait for its result. The company guides topline to the fourth quarter of 2026 with no scheduled date, so the readout, or a slip past 31 December 2026, settles the call.

The shares closed at $8.86 on 12 November 2026, down from $9.39 the session before. That is 41.5% below the 52-week intraday high of $15.15 set on 18 September 2026 and 26.1% lower than three months earlier. The 50-day average of $11.29 sits well above the close. The 200-day average of $7.78 sits below it.

The market has priced in a real chance that APPROACH misses: the 12 November 2026 close is far under both the 50-day average and Wells Fargo's $22 target of 22 October 2026. A positive result would likely move the shares sharply higher. The LOW rating says a binary Phase 3 outcome is less than an even bet to favour the shares over the index. It is not a forecast that the drug fails.

Company news since 2 November 2026 shows a Guggenheim Healthcare Innovation Conference appearance announced on 3 November 2026 and a report of insider cluster buying dated 2 November 2026. No topline result has been published as of 13 November 2026.

Bullish and bearish views on Cybin Inc.

The bull case on Cybin Inc. (HELP), in brief: late-stage asset with a defined readout. The bear case: one readout can end the case.

Bull case

• Late-stage asset with a defined readout. APPROACH completed enrollment of 223 adults ahead of schedule (company announcement, 21 July 2026). The company restated topline timing as the fourth quarter of 2026 in its fiscal first-quarter release of 14 August 2026 and at an investor presentation in October 2026.
• Insiders bought in September. SEC Form 4 filings show Chief Executive Officer Michael Halstead bought 100,000 shares at $13.47 on 21 September 2026. Director Eric So bought 100,000 at $12.09 on 4 September 2026 and 100,000 at $12.39 on 8 September 2026. Paul Glavine bought 100,000 at $12.47 on 8 September 2026, and Chief Financial Officer Greg Cavers bought 3,000 at $12.91 on 29 September 2026. Every one of these prices is above the 12 November 2026 close.
• Sell-side targets sit far above the price. Wells Fargo raised its target to $22 from $16 and kept an Overweight rating on 22 October 2026, reported by GuruFocus.
• A second pivotal study is enrolling. The company said enrollment continues in EMBRACE, the second Phase 3 study of the program, in its 21 July 2026 announcement.

Bear case

• One readout can end the case. HLP003 is the only late-stage asset. The company's anxiety program disappointed investors in March 2026, when the shares fell about a third on the day of the Phase 2 data. A miss on the six-week primary endpoint would remove the lead program.
• Cash use is rising. Cash was $166.4 million at 30 June 2026. Operating cash used in the quarter was $37.1 million versus $29.5 million a year earlier, and the net loss was $47.8 million versus $24.6 million (fiscal first-quarter 2027 release, 14 August 2026). The fiscal second-quarter report, for the quarter ended 30 September 2026, updates each figure.
• Leadership changed before the data. Halstead became chief executive on 3 August 2026. Co-founders Eric So and Paul Glavine left executive roles on 27 October 2026 and remain directors, and Mark Lawson became independent Board Chair (company release, 27 October 2026).
• The shares are weakening into the wait. The close of $8.86 on 12 November 2026 compares with $10.52 on 27 October 2026. No company release explains the decline.

Price setup

The shares closed at $8.86 on 12 November 2026, below the 50-day average of $11.29 and above the 200-day average of $7.78. Both averages are from adjusted daily closes. The three-month change is −26.1%, measured from the $11.99 close of 14 August 2026.

The nearest reference below is the $8.39 close of 5 November 2026, the lowest close of the past week. The 52-week closing low is $3.87 on 10 June 2026. The 52-week high of $15.15 came intraday on 18 September 2026, in the same month as the insider purchases above.

Float was 46.84 million of 61.98 million shares outstanding on 15 August 2026. A float that size lets the shares gap in either direction on a binary result.

Catalysts ahead

• ~16 November 2026 (est.): Fiscal second-quarter 2027 report for the quarter ended 30 September 2026; the company has not announced the date. Updates cash against $37.1 million of operating cash used in the June quarter and may restate the APPROACH timetable or announce financing.
• ~20 November 2026 (est.): APPROACH Phase 3 topline for HLP003, on TD Cowen's mid-November timing estimate of 20 August 2026; the company guides only to the fourth quarter of 2026. A statistically significant six-week gain over placebo on the Montgomery-Åsberg Depression Rating Scale shows whether the effect holds at Phase 3 scale; a miss removes the lead program.
• ~31 December 2026 (est.): End of the company's guided fourth-quarter 2026 topline window. No topline by this date would break the stated timetable.

What would change the view

A daily close above $11.55, which would show the shares leading again. A statistically significant six-week gain over placebo on the APPROACH primary endpoint would also show the call wrong.

What it trades with

Helus trades alongside the psychedelic-medicine group. On 16 July 2026 it appeared as a gainer beside ATAI and COMP in separate screens, so sector sentiment can move the shares without company news. The sample of group co-moves is too small to support a measured link.